Polymorphisms in TPT1 Pathways in Pediatric Astrocytomas

References

• Acunzo J., Baylot V., So A., et al. (2014). TCTP As therapeutic target in cancers. Cancer Treatment Reviews, 40, 760–769. https://doi.org/10.1016/j.ctrv.2014.02.007
   PubMed Web of Science ®Google Scholar
• Allred D. C., Harvey J. M., Berardo M., et al. (1998). Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathology, 11(2), 155–168.
   PubMed Web of Science ®Google Scholar
• Amson R., Karp J. E., Tellerman A. (2013). Lessons from tumor reversion for cancer treatment. Current Opinion in Oncology, 25, 59–65. https://doi.org/10.1097/CCO.0b013e32835b7d21
   PubMed Web of Science ®Google Scholar
• Amson R., Pece S., Marine J. P., et al. (2012). TPT1/ TCTP-regulated pathways in phenotypic reprogramming. Trends in Cell Biology, 1–10. https://doi.org/10.1016/j.tcb.2012.10.002
   Web of Science ®Google Scholar
• Baú-Carneiro J. L., Sumida I. A. G., Gallon M., et al. (2022). Sertraline repositioning: an overview of its potential use as a chemotherapeutic agent after four decades of tumor reversal studies. Trans Oncol.
   PubMed Web of Science ®Google Scholar
• Boia-Ferreira M., Basílio A. B., Hamasaki A. E., et al. (2017). TCTP as a therapeutic target in melanoma treatment. British Journal of Cancer.
   PubMed Web of Science ®Google Scholar
• Bommer U. A., Iadevai G., Chen J., et al. (2015). Growth-factor dependent expression of the translationally controlled tumour protein TCTP is regulated through the PI3-K/Akt/mTORC1 signalling pathway. Cellular Signalling, 27, 1557–1568. https://doi.org/10.1016/j.cellsig.2015.04.011
   PubMed Web of Science ®Google Scholar
• Bommer U. A., Thilele B. J. (2004). The translationally controlled tumour protein (TCTP). The International Journal of Biochemistry & Cell Biology, 36, 379–385.
   PubMed Web of Science ®Google Scholar
• Chanock S. (2001). Candidate genes and single nucleotide polymorphisms (SNPs) in the study of human disease. Disease Markers, 17, 89–98. https://doi.org/10.1155/2001/858760
   PubMed Web of Science ®Google Scholar
• Chaurasia A., Park S. H., Seo J. W., et al. (2016). Immunohistochemical analysis of ATRX, IDH1 and p53 in glioblastoma and their correlations with patient survival. Journal of Korean Medical Science, 31, 1208–1214. https://doi.org/10.3346/jkms.2016.31.8.1208
   PubMed Web of Science ®Google Scholar
• Chen C., Deng Y., Hua M., et al. (2015). Expression and clinical role of TCTP in epithelial ovarian cancer. J Mol Hist, 1–12. https://doi.org/10.1007/s10735-014-9599-7
   PubMed Web of Science ®Google Scholar
• Custodio G., Taques G. R., Figueiredo B. C., et al. (2011). Increased Incidence of Choroid Plexus Carcinoma Due to the Germline TP53 R337H Mutation in Southern Brazil. Plos One, 6. https://doi.org/10.1371/journal.pone.0018015
   PubMed Web of Science ®Google Scholar
• Drach L. M., Kammermeier M., Neirich U., et al. (1996). Accumulation of nuclear p53 protein and prognosis of astrocytomas in childhood and adolescence. Clinical Neuropathology, 15, 67–73.
   PubMed Web of Science ®Google Scholar
• Gansmo L. B., Knappskog S., Romundstad P., et al. (2015). Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung, and colon. International Journal of Cancer, 137, 96–103. https://doi.org/10.1002/ijc.29358
   PubMed Web of Science ®Google Scholar
• Gu X., Yao L., Ma G., et al. (2014). TCTP Promotes glioma cell proliferation in vitro and in vivo via enhanced b-catenin/TCF-4 transcription. Neuro-Oncology, 16(2), 217–227. https://doi.org/10.1093/neuonc/not194
   PubMed Web of Science ®Google Scholar
• Kreis N. N., Louwen F., Yuan J. (2019). The multifaceted p21 (Cip1/Waf1/CDKN1A) in cell differentiation, migration and cancer therapy. Cancers, 11, 1220. https://doi.org/10.3390/cancers11091220
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T., Bernig T., Hanisch M., et al. (2005). Common genetic variants in the interleukin-6 and chitotriosidase genes are associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia. Leukemia, 19, 1745–1750. https://doi.org/10.1038/sj.leu.2403922
   PubMed Web of Science ®Google Scholar
• Louis D. N. (2016). The 2016 WHO classification of tumours of the central nervous system. Acta Neuropathologica, 114, 97–109. https://doi.org/10.1007/s00401-007-0243-4
   Google Scholar
• Louis D. N., Perry A., Wesseling P., Brat D., Cree I., Hawkins C., et al. (2021). The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro-Oncology, 23(8), 1231–1251. https://doi.org/10.1093/neuonc/noab106
   PubMed Web of Science ®Google Scholar
• Mascelli S., Nozza P., Jones D. T. W., et al. (2016). TP53 codon 72 polymorphism may predict early tumour progression in paediatric pilocytic astrocytoma. Oncotarget, 7(30). https://doi.org/10.18632/oncotarget.10295
   PubMedGoogle Scholar
• Miao X., Chen Y. B., Xu S. L., et al. (2013). TCTP Overexpression is associated with the development and progression of glioma. Tumor Biology, 1–5.
   Google Scholar
• Moll U. M., Petrenko O. (2003). The MDM2-p53 interaction. Molecular Cancer Research, 1, 1001–1008.
   PubMed Web of Science ®Google Scholar
• NCBI (2022). Available at: https://www.ncbi.nlm.nih.gov/snp/?term=rs3176334 (accessed December 15, 2022).
   Google Scholar
• Ostrom Q., Patil N., Cioffi G., Waite K., Kruchki C., Barnholtz-Sloan J. (2020). CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro-Oncology, 12, 1–96. https://doi.org/10.1093/neuonc/noaa200
   Google Scholar
• Park H. S., Park J. M., Park S., et al. (2013). Subcellular localization of Mdm2 expression and prognosis of breast cancer. International Journal of Clinical Oncology, 1–10.
   Web of Science ®Google Scholar
• Pertovaara M., Antonen J., Hurme M. (2006). Th2 cytokine genotypes are associated with a milder form of primary sjogren’s syndrome. Annals of the Rheumatic Diseases, 65(5), 666–670. https://doi.org/10.1136/ard.2005.040956
   PubMed Web of Science ®Google Scholar
• Ribeiro R. C., Sandrini F., Figueiredo B. C., et al. (2001). An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. PNAS, 98. https://doi.org/10.1073/pnas.161479898
   Web of Science ®Google Scholar
• Rocca B. J., Gironi A., Barone A., et al. (2015). Translationally controlled tumor protein in prostatic adenocarcinoma: Correlation with tumor grading and treatment-related changes. BioMed Research International, 1–8. https://doi.org/10.1155/2015/985950
   Web of Science ®Google Scholar
• Roszak A., Misztal M., Sowinska A., et al. (2015). Murine double-minute 2 homolog single nucleotide polymorphisms 285 and 309 in cervical carcinogenesis. Mol DiagnTher, 19, 235–244.
   Google Scholar
• Ryall S., Taboti U., Hawkins C. (2020). Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathologica Communications, 8, 30. https://doi.org/10.1186/s40478-020-00902-z
   PubMed Web of Science ®Google Scholar
• Shamloo B., Usluer S. (2019). P21 in cancer research. Cancers, 11, 1178. https://doi.org/10.3390/cancers11081178
   PubMed Web of Science ®Google Scholar
• Silva-Camargo C. C. V., et al. (2018). Parkin protein expression and its impact on survival with advanced colorectal cancer. Cancer Biology & Medicine, 15, 61–69.
   PubMed Web of Science ®Google Scholar
• SNPinfo (2022). Available at: https://snpinfo.niehs.nih.gov (accessed on July 30, 2022).
   Google Scholar
• Tuynder M., Fiucci G., Prieur S., et al. (2004). Translationally controlled tumor protein is a target of tumor reversion. Proceedings of the National Academy of Sciences of the USA, 101(43), 15364–9. https://doi.org/10.1073/pnas.0406776101
   PubMed Web of Science ®Google Scholar
• Zhang J., Zhang Y., Zhang Z. (2018). Association of rs2279744 and rs117039649 promoter polymorphism with the risk of gynecological cancer. A meta-analysis of case–control studies. Medicine, 97, 1–9. https://doi.org/10.1097/MD.0000000000010109
   Web of Science ®Google Scholar